APO-Pemetrexed pemetrexed 100 mg (as disodium) powder for injection vial

País: Austràlia

Idioma: anglès

Font: Department of Health (Therapeutic Goods Administration)

ingredients actius:

pemetrexed disodium hemipentahydrate, Quantity: 120.8 mg (Equivalent: pemetrexed, Qty 100 mg)

Disponible des:

Arrotex Pharmaceuticals Pty Ltd

Designació comuna internacional (DCI):

pemetrexed disodium hemipentahydrate

formulario farmacéutico:

Injection, powder for

Composición:

Excipient Ingredients: mannitol; hydrochloric acid; sodium hydroxide

Vía de administración:

Intravenous Infusion

Unidades en paquete:

1

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Malignant Pleural Mesothelioma,Pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,Non-Small Cell Lung Cancer (NSCLC),Pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology.,Pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Resumen del producto:

Visual Identification: White to either light yellow or green-yellow powder.; Container Type: Vial; Container Material: Glass; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Estat d'Autorització:

Licence status A

Data d'autorització:

2014-09-04